Chimera and Tandem-Repeat Type Galectins: The New Targets for Cancer Immunotherapy

Chimera and Tandem-Repeat Type Galectins: The New Targets for Cancer Immunotherapy

In humans, a total of 12 galectins have been identified. Their intracellular and extracellular biological functions are explored and discussed in this review. These galectins play important roles in controlling immune responses within the tumour microenvironment (TME) and the infiltration of immune...

Full description

Bibliographic Details
Main Authors:	Frankie Chi Fat Ko, Sheng Yan, Ka Wai Lee, Sze Kwan Lam, James Chung Man Ho
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Series:	Biomolecules
Subjects:	galectins intracellular secretory immune checkpoint inhibitors immuno-oncology therapy
Online Access:	https://www.mdpi.com/2218-273X/13/6/902

Similar Items

Galectin-3 Expression in Human Endometrium and Decidua During The Menstrual Cycle and in Gestation
by: Nevra Dursun, et al.
Published: (2011-04-01)

Targeting intracellular galectins for cancer treatment
by: Rita Nehmé, et al.
Published: (2023-09-01)

Immunology of Cell Death in Cancer Immunotherapy
by: Lorenzo Galluzzi, et al.
Published: (2021-05-01)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
by: Joseph Mabbitt, et al.
Published: (2023-08-01)

Determination of galectin-3 expression in the tissue of follicular thyroid tumors
Published: (2011-03-01)

Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations
by: Madyson Colton, et al.
Published: (2020-11-01)

The role of biomarkers in personalized immunotherapy
by: Kamya Sankar, et al.
Published: (2022-05-01)

Plasma Galectin-9 Concentrations in Normal and Diseased Condition
by: Toshiro Niki, et al.
Published: (2018-11-01)

Role of Galectins in Multiple Myeloma
by: Paola Storti, et al.
Published: (2017-12-01)

A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)
by: Yan Lv, et al.
Published: (2023-11-01)

The Immunotherapy Landscape in Adrenocortical Cancer
by: Guillaume J. Pegna, et al.
Published: (2021-05-01)

Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells
by: Zoe Leung, et al.
Published: (2019-10-01)

Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape
by: Giorgia Scafetta, et al.
Published: (2024-02-01)

Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application
by: Shijia ZHANG, et al.
Published: (2017-09-01)

Future prospects for breast cancer immunotherapy
by: V. F. Semiglazov, et al.
Published: (2018-11-01)

Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?
by: Yuanwei Shi, et al.
Published: (2022-05-01)

Galectins from Onchocerca ochengi and O. volvulus and their immune recognition by Wistar rats, Gudali zebu cattle and human hosts
by: Ngwafu Nancy Ngwasiri, et al.
Published: (2021-01-01)

Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials
by: Daniel Compagno, et al.
Published: (2020-05-01)

Galectin-3 not Galectin-9 as a candidate prognosis marker for hepatocellular carcinoma
by: Fei Kong, et al.
Published: (2020-09-01)

Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach
by: Gillian Murtagh, et al.
Published: (2024-02-01)

The role of salivary galectin-3 and galectin-9 levels in plaque-induced gingivitis and periodontitis
by: Zerrin Barut, et al.
Published: (2023-09-01)

Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
by: Daniel Kreatsoulas, et al.
Published: (2022-06-01)

In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model
by: Hanwen Wang, et al.
Published: (2019-05-01)

A multiplexed assay for quantifying immunomodulatory proteins supports correlative studies in immunotherapy clinical trials
by: Jeffrey R. Whiteaker, et al.
Published: (2023-05-01)

High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients
by: Anna Trebo, et al.
Published: (2020-04-01)

Should We Design Clinical Trials Differently in the Era of Cancer Immunotherapy?
by: Chia-Chi Lin
Published: (2019-05-01)

Galectins as Cancer Biomarkers
by: Vitaly Balan, et al.
Published: (2010-04-01)

Autophagy Drives Galectin-1 Secretion From Tumor-Associated Macrophages Facilitating Hepatocellular Carcinoma Progression
by: Goutham Venkata Naga Davuluri, et al.
Published: (2021-09-01)

Galectin 3: an extraordinary multifunctional protein in dermatology. Current knowledge and perspectives
by: Efstathia Pasmatzi, et al.
Published: (2019-07-01)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
by: Robert W. Wilkinson, et al.
Published: (2018-06-01)

A Synthetic Tetramer of Galectin-1 and Galectin-3 Amplifies Pro-apoptotic Signaling by Integrating the Activity of Both Galectins
by: Shaheen A. Farhadi, et al.
Published: (2020-01-01)

A unique maternal and placental galectin signature upon SARS-CoV-2 infection suggests galectin-1 as a key alarmin at the maternal–fetal interface
by: Fangqi Zhao, et al.
Published: (2023-07-01)

Galectin-3 Inhibits Galectin-8/Parkin-Mediated Ubiquitination of Group A Streptococcus
by: Yi-Lin Cheng, et al.
Published: (2017-09-01)

Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice
by: Anna Chen, et al.
Published: (2023-05-01)

Pattern Analysis of Serum Galectins-1, -3, and -9 in Breast Cancer
by: Avery Funkhouser, et al.
Published: (2023-07-01)

Alternative metrics for assessing clinical benefit with immunotherapy in oncology
by: E. Chan, et al.
Published: (2019-10-01)

Characterising CD8+ T cell transcriptomic and clonal consequences of immune checkpoint blockade for the treatment of cancer
by: Watson, RA
Published: (2023)

Clinical Relevance of Galectin-1 and Galectin-3 in Rheumatoid Arthritis Patients: Differential Regulation and Correlation With Disease Activity
by: Santiago P. Mendez-Huergo, et al.
Published: (2019-01-01)

Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment
by: Victoria Sundblad, et al.
Published: (2021-04-01)

Preliminary report of a novel formulation of clinical-grade, fully matured, tumor-associated peptide-loaded dendritic cells for cancer immunotherapy
by: Leonardo Mirandola, et al.
Published: (2019-11-01)